MedPath

Entereg

These highlights do not include all the information needed to use ENTEREG safely and effectively. See full prescribing information for ENTEREG. ENTEREG (alvimopan) capsules, for oral use Initial U.S. Approval: 2008

Approved
Approval ID

77a67dc6-35d3-48ff-9d18-292d4d442f70

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 10, 2023

Manufacturers
FDA

Merck Sharp & Dohme LLC

DUNS: 118446553

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

alvimopan

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code67919-020
Application NumberNDA021775
Product Classification
M
Marketing Category
C73594
G
Generic Name
alvimopan
Product Specifications
Route of AdministrationORAL
Effective DateMay 11, 2022
FDA Product Classification

INGREDIENTS (3)

alvimopanActive
Quantity: 12 mg in 1 1
Code: 677C126AET
Classification: ACTIM
POLYETHYLENE GLYCOL, UNSPECIFIEDInactive
Code: 3WJQ0SDW1A
Classification: IACT
GELATIN, UNSPECIFIEDInactive
Code: 2G86QN327L
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Entereg - FDA Drug Approval Details